Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 23 May 2024Expected publication date: 21 August 2024
Pralsetinib for thyroid cancer [ID4018]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC